Marker Therapeutics, Inc. Common Stock (MRKR)

Price$1.45

Value ScoreB

Growth ScoreD

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)12.08%

Price vs S&P 500 (4W)-10.91%

VGM Score52.60

Market Capitalization$23.68M

All Metrics

Book Value / Share (Quarterly)$0.83

P/TBV (Annual)1.27x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-26.71%

Cash Flow / Share (Quarterly)$-0.47

Price vs S&P 500 (YTD)-16.09%

Net Profit Margin (TTM)-342.96%

EPS (TTM)$-0.90

10-Day Avg Trading Volume0.07M

EPS Excl Extra (TTM)$-0.90

Revenue Growth (5Y)49.81%

EPS (Annual)$-0.79

ROI (Annual)-72.42%

Net Profit Margin (5Y Avg)-892.83%

Cash / Share (Quarterly)$0.89

Revenue Growth QoQ (YoY)-51.00%

ROA (Last FY)-63.78%

Revenue Growth TTM (YoY)-46.19%

EBITD / Share (TTM)$-0.84

ROE (5Y Avg)-87.35%

Operating Margin (TTM)-363.45%

Cash Flow / Share (Annual)$-0.72

P/B Ratio1.72x

P/B Ratio (Quarterly)1.57x

Net Income / Employee (Annual)$-2,432,700

EV / Revenue (TTM)2.47x

Net Interest Coverage (TTM)-0.22x

ROA (TTM)-67.05%

EPS Incl Extra (Annual)$-0.79

Current Ratio (Annual)8.39x

Quick Ratio (Quarterly)4.68x

3-Month Avg Trading Volume0.14M

52-Week Price Return0.71%

Revenue / Employee (TTM)$709,300

Tangible BV / Share (Quarterly)$1.90

P/S Ratio (Annual)6.68x

Asset Turnover (Annual)0.19x

52-Week High$4.07

Operating Margin (5Y Avg)-936.98%

EPS Excl Extra (Annual)$-0.79

Tangible BV CAGR (5Y)39.90%

26-Week Price Return25.66%

Quick Ratio (Annual)8.10x

13-Week Price Return1.43%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)4.79x

Enterprise Value$8.76M

Revenue / Share Growth (5Y)18.30%

Asset Turnover (TTM)0.20x

Book Value / Share Growth (5Y)-28.53%

Revenue / Employee (Annual)$709,300

Pretax Margin (Annual)-343.39%

Cash / Share (Annual)$0.96

3-Month Return Std Dev68.36%

Net Income / Employee (TTM)$-2,432,700

ROE (Last FY)-72.42%

Net Interest Coverage (Annual)-33.36x

EPS Basic Excl Extra (Annual)$-0.79

Receivables Turnover (TTM)6.31x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.90

Receivables Turnover (Annual)7.50x

ROI (TTM)-80.86%

P/S Ratio (TTM)6.68x

Pretax Margin (5Y Avg)-927.83%

Revenue / Share (Annual)$0.23

Tangible BV / Share (Annual)$2.33

Price vs S&P 500 (52W)-27.44%

Year-to-Date Return-4.70%

5-Day Price Return-2.07%

EPS Normalized (Annual)$-0.79

ROA (5Y Avg)-61.80%

Net Profit Margin (Annual)-342.96%

Month-to-Date Return-9.55%

Cash Flow / Share (TTM)$-0.74

EBITD / Share (Annual)$-0.84

Operating Margin (Annual)-363.45%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-87.35%

EPS Basic Excl Extra (TTM)$-0.90

P/TBV (Quarterly)1.48x

P/B Ratio (Annual)1.48x

Pretax Margin (TTM)-343.39%

Book Value / Share (Annual)$1.01

Price vs S&P 500 (13W)-9.23%

Beta1.45x

Revenue / Share (TTM)$0.18

ROE (TTM)-80.86%

52-Week Low$0.81

vGradeB

gGradeD

mGradeC

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.16est. -0.19

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.11

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
MRKRMarker Therapeutics, Inc. Common Stock	B	D	C	$1.45
LLYEli Lilly & Co.	D	B	B	$1078.78
JNJJohnson & Johnson	C	C	C	$223.24
ABBVABBVIE INC.	D	C	C	$217.13
MRKMerck & Co., Inc.	C	C	C	$114.70
AZNAstraZeneca PLC	D	B	C	$176.28
NVSNovartis AG	C	C	C	$143.66
NVONovo-Nordisk A/S	B	B	B	$42.00
ABTAbbott Laboratories	C	C	D	$86.99
PFEPfizer Inc.	B	C	C	$25.34
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$32.83

About

Marker Therapeutics is a clinical-stage immuno-oncology company developing T cell-based immunotherapies and vaccine candidates for hematological and solid tumors. Its MultiTAA T cell technology selectively expands patient-derived, tumor-specific T cells to target and eliminate cancer cells expressing tumor-associated antigens.